Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept in Polypoidal Choroidal Vasculopathy
NCT02381730Completed
- Sponsor
- Adolphe de Rothschild Foundation Hospital
- Start
- Jan 2014
- Primary completion
- Aug 2017
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Open-label, single-arm trial of aflibercept in polypoidal choroidal vasculopathy (PCV), sponsored by Adolphe de Rothschild Foundation Hospital. Primary endpoint: Best Corrected Visual Acuity at 28 weeks. Started Jan 2014; status: completed.
02
Drugs
aflibercept
03
Conditions
polypoidal choroidal vasculopathy (PCV)
Beyond the preview
Go deeper on NCT02381730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02381730.